Muscles don’t grow bigger by filling up with water or energy stores—they grow by adding more contractile proteins that actually make you stronger.
Scientific Claim
Sarcoplasmic hypertrophy—defined as disproportionate expansion of non-contractile muscle components—is not a meaningful or persistent contributor to long-term muscle growth in humans, with myofibrillar protein accretion being the dominant adaptation.
Original Statement
“Evidence for sarcoplasmic hypertrophy as a distinct, functional contributor to muscle growth is weak; myofibrillar protein accretion remains the dominant adaptation.”
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design cannot support claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
The review uses definitive language ('remains the dominant adaptation') but synthesizes studies with conflicting results. The conclusion is evidence-based but the review cannot establish causation or long-term dominance.
More Accurate Statement
“Sarcoplasmic hypertrophy is unlikely to be a meaningful or persistent contributor to long-term muscle growth in humans, as current evidence suggests myofibrillar protein accretion remains the dominant adaptation.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aThe relative contribution of sarcoplasmic vs. myofibrillar protein accretion to muscle hypertrophy across training styles and populations.
The relative contribution of sarcoplasmic vs. myofibrillar protein accretion to muscle hypertrophy across training styles and populations.
What This Would Prove
The relative contribution of sarcoplasmic vs. myofibrillar protein accretion to muscle hypertrophy across training styles and populations.
Ideal Study Design
A meta-analysis of 25+ studies using muscle biopsy with proteomics or TEM to quantify sarcoplasmic and myofibrillar protein content changes after resistance training, stratified by training volume, load, and experience level.
Limitation: Heterogeneity in biopsy methods and protein quantification limits comparability.
Randomized Controlled TrialLevel 1bIn EvidenceCausal effect of high-volume vs. high-load training on sarcoplasmic vs. myofibrillar protein synthesis rates.
Causal effect of high-volume vs. high-load training on sarcoplasmic vs. myofibrillar protein synthesis rates.
What This Would Prove
Causal effect of high-volume vs. high-load training on sarcoplasmic vs. myofibrillar protein synthesis rates.
Ideal Study Design
A double-blind, crossover RCT with 20 trained men, comparing 12 weeks of high-volume (32 sets/week) vs. high-load (12 sets/week) leg training, measuring sarcoplasmic and myofibrillar MPS via D2O tracer and protein abundance via mass spectrometry.
Limitation: Cannot fully separate sarcoplasmic volume changes from hydration or glycogen.
Prospective Cohort StudyLevel 2bLong-term association between training style (bodybuilding vs. powerlifting) and muscle composition in elite athletes.
Long-term association between training style (bodybuilding vs. powerlifting) and muscle composition in elite athletes.
What This Would Prove
Long-term association between training style (bodybuilding vs. powerlifting) and muscle composition in elite athletes.
Ideal Study Design
A 5-year prospective cohort of 50 elite bodybuilders and 50 powerlifters, annually measuring muscle fiber CSA, myofibrillar density via TEM, and sarcoplasmic volume via MRI spectroscopy, controlling for nutrition and steroid use.
Limitation: Selection bias and confounding by steroid use in bodybuilders.
Evidence from Studies
Supporting (1)
Load-induced human skeletal muscle hypertrophy: Mechanisms, myths, and misconceptions.